The August edition of New Jersey Lawyer is dedicated to key topics on regulated substances in the state and the expanding role of attorneys in this practice area.
Drug law has evolved significantly since the emergence of medicinal cannabis and its expansion into adult-use markets. Today, the practice not only encompasses
cannabis, but psychedelics and grapples with broader questions about how regulated substances interact with the law. These issues span multiple industries, from health care and employment to real estate, intellectual property and insurance.
This issue of New Jersey Lawyer reflects on the far-reaching impact of drug law across four articles that cover insurer use artificial intelligence in health care, the future of psychedelics regulation, legal uncertainty in the intoxicating hemp industry and drug patent standards.
The edition features practice tips on how law lawyers can upgrade their clientele, learn to accept criticism and mater persuasive writing. The magazine also includes summer highlights from the New Jersey State Bar Association and a column from NJSBA President Christine A. Amalfe on the Association’s many benefits for young lawyers.
Here is the full list of articles from the edition:
· Insurer Use of AI in Medicine and Health Care Draws Expansive Scrutiny – By Robert B. Hille and John W. Kaveney
· What’s Next for Regulation of Psychedelics in New Jersey – By Joseph M. Shapiro
· New Jersey’s Intoxicating Hemp Industry Evolves Amid Legal Uncertainty – By John D. Williams
· Federal Circuit Affirms NJ District Court Teva Ruling, Refining Drug Patent Listing Standards – By Miriam Goldgeil
The full issue of New Jersey Lawyer is available on njsba.com.